PDCD1 and melanoma: The aim of this clinical trial was to evaluate the efficacy of Relatlimab as a monotherapy or in combination with Nivolumab (anti-PD-1 antibody) in patients with various advanced malignancies including melanoma, NSCLC, and RCC [20].